{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:28:04Z","timestamp":1784917684497,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T00:00:00Z","timestamp":1685059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    BOADICEA is a comprehensive risk prediction model for breast and\/or ovarian cancer (BC\/OC) and for carrying pathogenic variants (PVs) in cancer susceptibility genes. In addition to\n                    <jats:italic>BRCA1<\/jats:italic>\n                    and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    , BOADICEA version 6 includes\n                    <jats:italic>PALB2<\/jats:italic>\n                    ,\n                    <jats:italic>CHEK2<\/jats:italic>\n                    ,\n                    <jats:italic>ATM<\/jats:italic>\n                    ,\n                    <jats:italic>BARD1<\/jats:italic>\n                    ,\n                    <jats:italic>RAD51C<\/jats:italic>\n                    and\n                    <jats:italic>RAD51D<\/jats:italic>\n                    . To validate its predictions for these genes, we conducted a retrospective study including 2033 individuals counselled at clinical genetics departments in Denmark. All counselees underwent comprehensive genetic testing by next generation sequencing on suspicion of hereditary susceptibility to BC\/OC. Likelihoods of PVs were predicted from information about diagnosis, family history and tumour pathology. Calibration was examined using the observed-to-expected ratio (O\/E) and discrimination using the area under the receiver operating characteristics curve (AUC). The O\/E was 1.11 (95% CI 0.97\u20131.26) for all genes combined. At sub-categories of predicted likelihood, the model performed well with limited misestimation at the extremes of predicted likelihood. Discrimination was acceptable with an AUC of 0.70 (95% CI 0.66\u20130.74), although discrimination was better for\n                    <jats:italic>BRCA1<\/jats:italic>\n                    and\n                    <jats:italic>BRCA2<\/jats:italic>\n                    than for the other genes in the model. This suggests that BOADICEA remains a valid decision-making aid for determining which individuals to offer comprehensive genetic testing for hereditary susceptibility to BC\/OC despite suboptimal calibration for individual genes in this population.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-35755-8","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T06:03:19Z","timestamp":1685080999000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes"],"prefix":"10.1038","volume":"13","author":[{"given":"Nanna B\u00e6k","family":"M\u00f8ller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desir\u00e9e Sofie","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth Simone","family":"Feldner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Vibeke","family":"L\u00e6nkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5ke","family":"Borg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Kvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"T\u00f6rngren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe Birk","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne Eriksen","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorkild","family":"Terkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,26]]},"reference":[{"issue":"5","key":"35755_CR1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling, L. et al. Breast cancer risk genes: Association analysis in more than 113,000 women. N. Engl. J. Med. 384(5), 428\u2013439 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"35755_CR2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41571-021-00491-3","volume":"18","author":"WD Foulkes","year":"2021","unstructured":"Foulkes, W. D. The ten genes for breast (and ovarian) cancer susceptibility. Nat. Rev. Clin. Oncol. 18(5), 259\u2013260 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"35755_CR3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4247-z","volume":"164","author":"JA Cintolo-Gonzalez","year":"2017","unstructured":"Cintolo-Gonzalez, J. A. et al. Breast cancer risk models: A comprehensive overview of existing models, validation, and clinical applications. Breast Cancer Res Treat. 164(2), 263\u2013284 (2017).","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"35755_CR4","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.bjc.6602175","volume":"91","author":"AC Antoniou","year":"2004","unstructured":"Antoniou, A. C., Pharoah, P. P., Smith, P. & Easton, D. F. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br. J. Cancer. 91(8), 1580\u20131590 (2004).","journal-title":"Br. J. Cancer."},{"issue":"7","key":"35755_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/jmg.2007.056556","volume":"45","author":"AC Antoniou","year":"2008","unstructured":"Antoniou, A. C. et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: Validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J. Med. Genet. 45(7), 425\u2013431 (2008).","journal-title":"J. Med. Genet."},{"issue":"6","key":"35755_CR6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/jmedgenet-2012-101415","volume":"50","author":"C Fischer","year":"2013","unstructured":"Fischer, C. et al. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1\/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J. Med. Genet. 50(6), 360\u2013367 (2013).","journal-title":"J. Med. Genet."},{"issue":"12","key":"35755_CR7","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/gim.2016.31","volume":"18","author":"AJ Lee","year":"2016","unstructured":"Lee, A. J. et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet. Med. 18(12), 1190\u20131198 (2016).","journal-title":"Genet. Med."},{"key":"35755_CR8","first-page":"1","volume":"1","author":"A Lee","year":"2022","unstructured":"Lee, A. et al. Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1 updates to tumour pathology and cancer incidence. J. Med. Genet. 1, 1\u201312 (2022).","journal-title":"J. Med. Genet."},{"issue":"4","key":"35755_CR9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s10689-019-00141-9","volume":"18","author":"T Terkelsen","year":"2019","unstructured":"Terkelsen, T. et al. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: Analysis of 173 Danish breast cancer pedigrees using the BOADICEA model. Fam. Cancer. 18(4), 381\u2013388 (2019).","journal-title":"Fam. Cancer."},{"issue":"1","key":"35755_CR10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1309\/4WV79N2GHJ3X1841","volume":"123","author":"M Nadji","year":"2005","unstructured":"Nadji, M., Gomez-Fernandez, C., Ganjei-Azar, P. & Morales, A. R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am. J. Clin. Pathol. 123(1), 21\u201327 (2005).","journal-title":"Am. J. Clin. Pathol."},{"issue":"7 Suppl","key":"35755_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen, C. B. The Danish civil registration system. Scand. J. Public Health. 39(7 Suppl), 22\u201325 (2011).","journal-title":"Scand. J. Public Health."},{"key":"35755_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CLEP.S9908","volume":"2","author":"R Erichsen","year":"2010","unstructured":"Erichsen, R. et al. Existing data sources for clinical epidemiology: The Danish National Pathology Registry and Data Bank. Clin. Epidemiol. 2, 51\u201356 (2010).","journal-title":"Clin. Epidemiol."},{"issue":"5","key":"35755_CR13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","volume":"93","author":"B Rockhill","year":"2001","unstructured":"Rockhill, B., Spiegelman, D., Byrne, C., Hunter, D. J. & Colditz, G. A. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J. Natl. Cancer Inst. 93(5), 358\u2013366 (2001).","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"35755_CR14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper, C. J. & Pearson, E. S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26(4), 404\u2013413 (1934).","journal-title":"Biometrika"},{"issue":"1","key":"35755_CR15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","volume":"143","author":"JA Hanley","year":"1982","unstructured":"Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143(1), 29\u201336 (1982).","journal-title":"Radiology"},{"issue":"3","key":"35755_CR16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44(3), 837\u2013845 (1988).","journal-title":"Biometrics"},{"issue":"1","key":"35755_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/bcr1365","volume":"8","author":"AC Antoniou","year":"2006","unstructured":"Antoniou, A. C. et al. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res. 8(1), 3 (2006).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"35755_CR18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10689-011-9495-1","volume":"11","author":"AK Stahlbom","year":"2012","unstructured":"Stahlbom, A. K., Johansson, H., Liljegren, A., von Wachenfeldt, A. & Arver, B. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer. Fam. Cancer. 11(1), 33\u201340 (2012).","journal-title":"Fam. Cancer."},{"issue":"6","key":"35755_CR19","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.breast.2013.07.053","volume":"22","author":"L Varesco","year":"2013","unstructured":"Varesco, L. et al. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: A retrospective study in a sample of Italian cancer genetics clinics. Breast 22(6), 1130\u20131135 (2013).","journal-title":"Breast"},{"issue":"4","key":"35755_CR20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","volume":"26","author":"M Weischer","year":"2008","unstructured":"Weischer, M., Bojesen, S. E., Ellervik, C., Tybjaerg-Hansen, A. & Nordestgaard, B. G. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: Meta-analyses of 26,000 patient cases and 27,000 controls. J. Clin. Oncol. 26(4), 542\u2013548 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"35755_CR21","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1158\/1055-9965.EPI-08-1090","volume":"18","author":"AW Kurian","year":"2009","unstructured":"Kurian, A. W. et al. Performance of prediction models for BRCA mutation carriage in three racial\/ethnic groups: Findings from the Northern California Breast Cancer Family Registry. Cancer Epidemiol. Biomarkers Prev. 18(4), 1084\u20131091 (2009).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"4","key":"35755_CR22","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1186\/bcr2118","volume":"10","author":"E Thirthagiri","year":"2008","unstructured":"Thirthagiri, E. et al. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res. 10(4), R59 (2008).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"35755_CR23","doi-asserted-by":"crossref","first-page":"10229","DOI":"10.1038\/s41598-019-46707-6","volume":"9","author":"FH Hung","year":"2019","unstructured":"Hung, F. H. et al. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan. Sci. Rep. 9(1), 10229 (2019).","journal-title":"Sci. Rep."},{"issue":"14","key":"35755_CR24","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.21.01647","volume":"40","author":"BH Ang","year":"2022","unstructured":"Ang, B. H. et al. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation in Asian patients with breast cancer. J. Clin. Oncol. 40(14), 1542\u20131551 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"35755_CR25","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6604305","volume":"98","author":"AC Antoniou","year":"2008","unstructured":"Antoniou, A. C. et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: Updates and extensions. Br. J. Cancer. 98(8), 1457\u20131466 (2008).","journal-title":"Br. J. Cancer."},{"issue":"2","key":"35755_CR26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/bjc.2013.730","volume":"110","author":"AJ Lee","year":"2014","unstructured":"Lee, A. J. et al. BOADICEA breast cancer risk prediction model: Updates to cancer incidences, tumour pathology and web interface. Br. J. Cancer. 110(2), 535\u2013545 (2014).","journal-title":"Br. J. Cancer."},{"issue":"1","key":"35755_CR27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13073-022-01027-9","volume":"14","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. DrABC: Deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data. Genome Med. 14(1), 21 (2022).","journal-title":"Genome Med."},{"issue":"12","key":"35755_CR28","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41416-021-01580-x","volume":"125","author":"AL Blackford","year":"2021","unstructured":"Blackford, A. L. et al. A risk prediction tool for individuals with a family history of breast, ovarian, or pancreatic cancer: BRCAPANCPRO. Br. J. Cancer. 125(12), 1712\u20131717 (2021).","journal-title":"Br. J. Cancer."},{"issue":"7","key":"35755_CR29","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/jmedgenet-2015-103077","volume":"52","author":"S Jervis","year":"2015","unstructured":"Jervis, S. et al. A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J. Med. Genet. 52(7), 465\u2013475 (2015).","journal-title":"J. Med. Genet."},{"issue":"7","key":"35755_CR30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jmedgenet-2021-107904","volume":"59","author":"A Lee","year":"2022","unstructured":"Lee, A. et al. Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. J. Med. Genet. 59(7), 632\u2013643 (2022).","journal-title":"J. Med. Genet."},{"issue":"5","key":"35755_CR31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/jmedgenet-2019-106739","volume":"58","author":"H Song","year":"2021","unstructured":"Song, H. et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J. Med. Genet. 58(5), 305\u2013313 (2021).","journal-title":"J. Med. Genet."},{"issue":"11","key":"35755_CR32","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1038\/ejhg.2016.57","volume":"24","author":"H Byers","year":"2016","unstructured":"Byers, H. et al. Sensitivity of BRCA1\/2 testing in high-risk breast\/ovarian\/male breast cancer families: Little contribution of comprehensive RNA\/NGS panel testing. Eur. J. Hum. Genet. 24(11), 1591\u20131597 (2016).","journal-title":"Eur. J. Hum. Genet."},{"issue":"5","key":"35755_CR33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17(5), 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"35755_CR34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne, J. A. et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 338, b2393 (2009).","journal-title":"BMJ"},{"issue":"1","key":"35755_CR35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1080\/0284186X.2019.1648860","volume":"59","author":"T Terkelsen","year":"2020","unstructured":"Terkelsen, T., Ronning, H. & Skytte, A. B. Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer. Acta Oncol. 59(1), 60\u201365 (2020).","journal-title":"Acta Oncol."},{"issue":"4","key":"35755_CR36","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1399-0004.2009.01329.x","volume":"77","author":"AB Skytte","year":"2010","unstructured":"Skytte, A. B. et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: Uptake and timing. Clin. Genet. 77(4), 342\u2013349 (2010).","journal-title":"Clin. Genet."},{"issue":"1","key":"35755_CR37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/cge.13065","volume":"93","author":"S Moghadasi","year":"2018","unstructured":"Moghadasi, S. et al. Performance of BRCA1\/2 mutation prediction models in male breast cancer patients. Clin. Genet. 93(1), 52\u201359 (2018).","journal-title":"Clin. Genet."},{"issue":"3","key":"35755_CR38","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/bcr2576","volume":"12","author":"N Mavaddat","year":"2010","unstructured":"Mavaddat, N., Rebbeck, T. R., Lakhani, S. R., Easton, D. F. & Antoniou, A. C. Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res. 12(3), R28 (2010).","journal-title":"Breast Cancer Res."},{"issue":"5","key":"35755_CR39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/bjc.2013.382","volume":"109","author":"RJ MacInnis","year":"2013","unstructured":"MacInnis, R. J. et al. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre. Br. J. Cancer. 109(5), 1296\u20131301 (2013).","journal-title":"Br. J. Cancer."},{"issue":"11","key":"35755_CR40","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/s41436-020-0884-4","volume":"22","author":"IMM Lakeman","year":"2020","unstructured":"Lakeman, I. M. M. et al. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. Genet. Med. 22(11), 1803\u20131811 (2020).","journal-title":"Genet. Med."},{"issue":"3","key":"35755_CR41","first-page":"021","volume":"5","author":"SX Li","year":"2021","unstructured":"Li, S. X. et al. Prospective evaluation of the addition of polygenic risk scores to breast cancer risk models. JNCI Cancer Spectr. 5(3), 021 (2021).","journal-title":"JNCI Cancer Spectr."},{"issue":"1","key":"35755_CR42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13058-021-01399-7","volume":"23","author":"P Pal Choudhury","year":"2021","unstructured":"Pal Choudhury, P. et al. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. Breast Cancer Res. 23(1), 22 (2021).","journal-title":"Breast Cancer Res."},{"issue":"12","key":"35755_CR43","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/jmg-2022-108806","volume":"59","author":"X Yang","year":"2022","unstructured":"Yang, X. et al. Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study. J. Med. Genet. 59(12), 1196\u20131205 (2022).","journal-title":"J. Med. Genet."},{"key":"35755_CR44","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1136\/bmj.g7594","volume":"350","author":"GS Collins","year":"2015","unstructured":"Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. BMJ 350, 7594 (2015).","journal-title":"BMJ"}],"updated-by":[{"DOI":"10.1038\/s41598-023-42606-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35755-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35755-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T06:09:03Z","timestamp":1700460543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35755-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,26]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35755"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35755-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2158118\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-2158118\/v2","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,26]]},"assertion":[{"value":"1 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-023-42606-z","URL":"https:\/\/doi.org\/10.1038\/s41598-023-42606-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8536"}}